Korsana Biosciences disclosed a $175 million financing to advance a platform engineered to ferry antibodies across the blood‑brain barrier for Alzheimer’s disease and other neurologic indications. The company’s technology aims to improve central nervous system delivery by leveraging molecular engineering to increase brain exposure. Korsana’s approach tracks several industry efforts—Roche and AbbVie have clinical‑stage programs with similar brain‑delivery strategies—so clinical differentiation will hinge on safety, target engagement, and CNS exposure. The financing positions Korsana to move lead candidates into IND‑enabling studies or early clinical testing.